Let's make up the rumour from the posts here.
Word is, Benitec is about to merge with 4D Molecular Therapeutics, with a view to fast-tracking AMD. The new enity will be called Vespers Biopharma and will seek to raise $50M in a secondary public offering managed by RA Capital.